- Record: found
- Abstract: found
- Article: not found
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.
Darron R Brown
1 ,
Susanne K Kjaer ,
Kristján Sigurdsson ,
Ole-Erik Iversen ,
Mauricio Hernandez-Avila ,
Cosette M Wheeler ,
Gonzalo Perez ,
Laura A Koutsky ,
Eng Hseon Tay ,
Patricía Garcia ,
Kevin A Ault ,
Suzanne M Garland ,
Sepp Leodolter ,
Sven-Eric Olsson ,
Grace W K Tang ,
Daron G Ferris ,
Jorma Paavonen ,
Marc Steben ,
F Xavier Bosch ,
Joakim Dillner ,
Elmar A Joura ,
Robert J Kurman ,
Slawomir Majewski ,
Nubia Muñoz ,
Evan R Myers ,
Luisa L Villa ,
Frank J Taddeo ,
Christine Roberts ,
Amha Tadesse ,
Janine Bryan ,
Lisa C Lupinacci ,
Katherine E D Giacoletti ,
Heather L Sings ,
Margaret James ,
Teresa M Hesley ,
Eliav Barr
Apr 01 2009
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Human papillomavirus (HPV)-6/11/16/18 vaccine reduces the risk of HPV-6/11/16/18-related cervical intraepithelial neoplasia (CIN) 1-3 or adenocarcinoma in situ (AIS). Here, its impact on CIN1-3/AIS associated with nonvaccine oncogenic HPV types was evaluated.